953408-82-7

Basic information

• Product Name: 2,3-DIHYDRO-1-BENZOFURAN-7-SULFONYL CHLORIDE
• Synonyms: 2,3-DIHYDRO-1-BENZOFURAN-7-SULFONYL CHLORIDE;2,3-Dihydro-benzofuran-7-sulphonylchloride;2,3-Dihydro-benzofuran-7-sulfonyl chloride
• CAS NO: 953408-82-7
• Molecular Formula: C₈H₇ClO₃S
• Molecular Weight: 218.66
• Mol File: 953408-82-7.mol

Chemical Properties

• Boiling Point: 349.8±31.0 °C(Predicted)
• Appearance: /
• Density: 1.495±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 2,3-DIHYDRO-1-BENZOFURAN-7-SULFONYL CHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3-DIHYDRO-1-BENZOFURAN-7-SULFONYL CHLORIDE(953408-82-7)
• EPA Substance Registry System: 2,3-DIHYDRO-1-BENZOFURAN-7-SULFONYL CHLORIDE(953408-82-7)

Safety Data

• Hazardous Substances Data: 953408-82-7(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
2,3-Dihydro-1-benzofuran-7-sulfonyl chloride is used as a versatile reagent for the preparation of different functionalized benzofuran derivatives. Its role in organic synthesis is crucial for the development of new chemical entities with potential applications across various fields.
Used in Pharmaceutical Research:
In pharmaceutical research, 2,3-dihydro-1-benzofuran-7-sulfonyl chloride is utilized as a key intermediate for the synthesis of pharmaceuticals. Its ability to form benzofuran derivatives makes it a valuable component in the creation of new drugs with potential therapeutic benefits.
Used in Agrochemical Development:
2,3-Dihydro-1-benzofuran-7-sulfonyl chloride also finds application in the agrochemical industry. It is used in the synthesis of compounds that can be developed into new agrochemicals, contributing to the advancement of products for agricultural use.
Overall, 2,3-dihydro-1-benzofuran-7-sulfonyl chloride is a significant chemical entity in the realms of organic synthesis, pharmaceuticals, and agrochemicals due to its capacity to form a wide array of functionalized benzofuran derivatives.

Upstream product

• 206347-30-0 7-bromo-2,3-dihydrobenzofuran 
• 206347-32-2 1,3-dibromo-2-(2-bromoethoxy)benzene 
• 496-16-2 2.3-dihydrobenzofuran 

Relevant articles and documents

CONDENSED HETEROCYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY

The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I) wherein R1, A, B, D, E, G, Q, Ar, n, m, and p are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

ACYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY

The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I): wherein R1, R2, R5, Q, G, Ar, m, and n are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

4'-AMINO CYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY

The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I): formula (I) wherein Cy is selected from formula (Il) and wherein R1, R2, R3, Q, G, Ar, m, n and p are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

PYRROLIDINE-SUBSTITUTED AZAINDOLE COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY

The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I): wherein R1, R2, A, B, D, E, G, Ar, and n are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

ALKYL-SUBSTITUTED 3' COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY

The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I): wherein R1, R2, Ar, m and n are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

3' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY

The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I): wherein Q, R1, R4, m and Ar are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

4' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY

The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I): wherein R1, R2, R5, R6, B, D, E, G, Q, x and n are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

6' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY

The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I): wherein R1—R4 A, B, D, E, and G are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

Thrombin inhibitors having a lactam at P3

The present invention provides compounds having a lactam ring at P3 and at P1 have a six-membered heterocyclic ring having two ring nitrogen ring atoms and the remainder of the ring atoms carbon atoms. These compounds have biological activity as active and potent inhibitors of thrombin. Their pharmaceutically acceptable salts, pharmaceutical compositions thereof and methods of using these compounds and pharmaceutical compositions comprising these compounds as therapeutic agents for treatment of disease states in mammals which are characterized by abnormal thrombosis are also described.